Cat. No. | Product name | CAS No. | Purity | Chemical Structure |
---|---|---|---|---|
T12372 | PAT-505 | 1782070-22-7 | 98.84% |
|
PAT-505 is an orally available, selective and potent inhibitor of autologous epidermal growth factor (IC50 2 nM in Hep3B cells, 9.7 nM in human blood, 62 nM in m... | ||||
T2610 | BMS-599626 | 714971-09-2 | 98.73% |
|
BMS-599626 (AC480) has been used in trials studying the treatment of Cancer, Metastases, and HER2 or EGFR Expressing Advanced Solid Malignancies. | ||||
T2460 | JAK 3 inhibitor IV | 58753-54-1 | 98% |
|
JAK 3 inhibitor IV (ZM 39923 hydrochloride) is a JAK1/3 inhibitor with pIC50 of 4.4/7.1, almost no activity to JAK2 and modestly potent to EGFR; also found to be... | ||||
T12175 | Naquotinib mesylate | 1448237-05-5 |
|
|
Naquotinib mesylate (ASP8273 (mesylate)) is an orally available, mutant-selective and irreversible inhibitor of EGFR(iC50s of 8-33 nM and 230 nM for toward EGFR ... | ||||
T3P2855 | Chamigrenal | 19912-84-6 |
|
|
β-Chamigrenal has anti-inflammatory activity, it has inhibitory effects on lipopolysaccharide-induced nitric oxide and prostaglandin E2 production in RAW 264.7 m... | ||||
T13559 | Astragaloside VI | 84687-45-6 | 98% |
|
Astragaloside VI could improve wound healing by activating the EGFR/ERK signaling pathway. | ||||
T14677 | BMS-690514 | 859853-30-8 | 98% |
|
BMS-690514 is a potent and orally active inhibitor of EGFR and VEGFR. It has IC50s of 5, 20 and 60 nM for EGFR, HER 2 and HER 4, respectively. | ||||
TN3042 | 4-Hydroxycinnamamide | 194940-15-3 | 98% |
|
4-Hydroxycinnamamide has antioxidant activity. 4-Hydroxycinnamamide derivatives are specific inhibitors of tyrosine-specific protein kinases. | ||||
T11164 | EGFR mutant-IN-1 | T11164 | 98% |
|
EGFR mutant- in-1, A 5-methylpyrimidopyridone derivative are effective selective EGFRL858R/T790M/C797S mutant inhibitors with IC50 of 27.5 nM, which significantl... | ||||
T78326 | Depatuxizumab | 1471999-69-5 | 98% |
Depatuxizumab
|
Depatuxizumab, a brain-penetrant, humanized anti-EGFR monoclonal antibody, selectively inhibits the growth of mutant EGFRvIII and wild-type EGFR xenograft models... | ||||
T78335 | Inetetamab | 98% |
Inetetamab
|
|
Inetetamab, a monoclonal antibody, targets domain IV of the HER2 receptor and demonstrates antitumor activities both as a standalone therapy and when combined wi... | ||||
T78574 | EGFR-IN-85 | 1956378-29-2 | 98% |
|
EGFR-IN-85 (Compound 1), an EGFR inhibitor, exhibits potent activity with an IC50 of 0.19 μM against EGFRvⅢ phosphorylation and can suppress intratumoral EGFR si... | ||||
T78634 | 2′-Thioadenosine | 136904-69-3 | 98% |
|
2'-Thioadenosine (PD157432) serves as a selective and irreversible inhibitor of ErbB-1 and ErbB-2 tyrosine kinases, demonstrating an IC50 value of 45 µM against ... | ||||
T78788 | EGFR-IN-82 | 2568086-81-5 | 98% |
|
EGFR-IN-82 (Compound 8a) is a potent, orally active inhibitor of EGFR, exhibiting IC50 values of 0.09 nM for EGFR L858R/T790M/C797S and 0.06 nM for EGFR Del19/T7... | ||||
T78849 | EGFR/BRAFV600E-IN-2 | 98% |
|
|
E07 Aptamer, targeting the human epidermal growth factor receptor (hEGFR), competes with epidermal growth factor (EGF) for binding to a unique epitope on EGFR. T... | ||||
T78850 | EGFR/BRAFV600E-IN-3 | 98% |
|
|
EGFR/BRAFV600E-IN-3 is an inhibitor targeting EGFR, BRAFV600E, and EGFRT790M with IC50 values of 57 nM, 68 nM, and 9.70 nM, respectively. It induces apoptosis an... | ||||
T78862 | EGFR-IN-86 | 98% |
|
|
EGFR-IN-86 (compound 4i), an EGFR inhibitor (IC50: 1.5 nM), demonstrates potent activity against glioblastoma by inducing apoptosis and causing G2/M phase cell c... | ||||
T78877 | MTX-241F | 98% |
|
|
MTX-241F, a selective small molecule inhibitor, targets members of the EGFR and PI3 kinase families. It penetrates the blood-brain barrier, providing long-term t... | ||||
T79124 | JGK-068S | 2490431-16-6 | 98% |
|
Compound I (JGK-068S) is a potent inhibitor of the epidermal growth factor receptor (EGFR) [1]. | ||||
T79152 | PROTAC EGFR degrader 8 | 2925923-46-0 | 98% |
|
PROTAC EGFR degrader 8 (T-184) is a PROTAC that selectively degrades the epidermal growth factor receptor (EGFR) with a DC50 of 15.56 nM in HCC827 cells. It effe... |